{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T04:15:47Z","timestamp":1648786547018},"reference-count":25,"publisher":"Bentham Science Publishers Ltd.","issue":"46","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2019,4,26]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Heart failure with preserved ejection fraction (HFpEF) is associated with increased risk\nfor hospitalization and all-cause mortality. Currently, there is no established treatment to improve the survival of\nthese patients. Aldosterone appears to play a role in the pathogenesis of HFpEF.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>To discuss the findings of studies that evaluated the effects of mineralocorticoid receptor (MR) antagonists\non the outcome of patients with HFpEF.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>PubMed was searched for relevant papers. References of retrieved articles were also evaluated for\npertinent material.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Accumulating data suggest that MR antagonists might be useful in the management of patients with\nHFpEF. However, existing evidence is limited and conflicting.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions:<\/jats:title>\n<jats:p>More studies are needed to clearly define the therapeutic potential of MR antagonists in HFpEF.\nGiven the heterogeneity of this disease and the low specificity of the criteria used for its diagnosis, it is also important\nto improve the definition of HFpEF and include appropriately selected patients in these studies.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1381612825666190219140342","type":"journal-article","created":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T11:07:28Z","timestamp":1551179248000},"page":"5525-5527","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Role of Mineralocorticoid Receptor Antagonists in the Management of Heart Failure with Preserved Ejection Fraction"],"prefix":"10.2174","volume":"24","author":[{"given":"Achilleas","family":"Papagiannis","sequence":"first","affiliation":[{"name":"First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stelina","family":"Alkagiet","sequence":"additional","affiliation":[{"name":"First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Tziomalos","sequence":"additional","affiliation":[{"name":"First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski P.","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD. Eur Heart J, 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC., 2016, 37, 2129-2200,","journal-title":"Eur Heart J"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchf.2012.10.002","volume":"1","author":"Braunwald E.","year":"2013","unstructured":"Braunwald E. JACC Heart Fail, Heart failure., 2013, 1, 1-20,","journal-title":"JACC Heart Fail"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1161\/CIRCULATIONAHA.108.815944","volume":"119","author":"Lee D.S.","year":"2009","unstructured":"Lee DS, Gona P, Vasan RS. Circulation, Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the national heart, lung, and blood institute., 2009, 119, 3070-3077,","journal-title":"Circulation"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1161\/CIRCHEARTFAILURE.110.959890","volume":"4","author":"Haass M.","year":"2011","unstructured":"Haass M, Kitzman DW, Anand IS. Circ Heart Fail, Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial., 2011, 4, 324-331,","journal-title":"Circ Heart Fail"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/eurheartj\/ehr254","volume":"33","author":"","year":"2012","unstructured":". Eur Heart J, The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: An individual patient data meta-analysis., 2012, 33, 1750-1757,","journal-title":"Eur Heart J"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1161\/CIRCHEARTFAILURE.109.867044","volume":"3","author":"Prasad A.","year":"2010","unstructured":"Prasad A, Hastings JL, Shibata S. Circ Heart Fail, Characterization of static and dynamic left ventricular diastolic function in patients with heart failure with a preserved ejection fraction., 2010, 3, 617-626,","journal-title":"Circ Heart Fail"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/eurheartj\/ehq426","volume":"32","author":"Borlaug B.A.","year":"2011","unstructured":"Borlaug BA, Paulus WJ. Eur Heart J, Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment., 2011, 32, 670-679,","journal-title":"Eur Heart J"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1161\/CIRCHEARTFAILURE.109.931451","volume":"4","author":"Westermann D.","year":"2011","unstructured":"Westermann D, Lindner D, Kasner M. Circ Heart Fail, Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction., 2011, 4, 44-52,","journal-title":"Circ Heart Fail"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1006\/jmcc.1993.1066","volume":"25","author":"Brilla C.G.","year":"1993","unstructured":"Brilla CG, Matsubara LS, Weber KT. J Mol Cell Cardiol, Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism., 1993, 25, 563-575,","journal-title":"J Mol Cell Cardiol"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1161\/01.CIR.92.2.175","volume":"92","author":"Lomb\u00e8s M.","year":"1995","unstructured":"Lomb\u00e8s M, Alfaidy N, Eugene E, Lessana A, Farman N, Bonvalet JP. Circulation, Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart., 1995, 92, 175-182,","journal-title":"Circulation"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"16633","DOI":"10.1074\/jbc.M109.008748","volume":"284","author":"Bunda S.","year":"2009","unstructured":"Bunda S, Wang Y, Mitts TF. J Biol Chem, Aldosterone stimulates elastogenesis in cardiac fibroblasts via mineralocorticoid receptor-independent action involving the consecutive activation of Galpha13, c-Src, the insulin-like growth factor-I receptor, and phosphatidylinositol 3-kinase\/Akt., 2009, 284, 16633-16647,","journal-title":"J Biol Chem"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1161\/01.RES.0000159937.05502.d1","volume":"96","author":"Jaffe I.Z.","year":"2005","unstructured":"Jaffe IZ, Mendelsohn ME. Circ Res, Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells., 2005, 96, 643-650,","journal-title":"Circ Res"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0039-128X(99)00087-2","volume":"65","author":"Rogerson F.M.","year":"2000","unstructured":"Rogerson FM, Fuller PJ. Steroids, Mineralocorticoid action., 2000, 65, 61-73,","journal-title":"Steroids"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/nm.2891","volume":"18","author":"McCurley A.","year":"2012","unstructured":"McCurley A, Pires PW, Bender SB. Nat Med, Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors., 2012, 18, 1429-1433,","journal-title":"Nat Med"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1161\/01.RES.36.2.300","volume":"36","author":"Gavras H.","year":"1975","unstructured":"Gavras H, Brunner HR, Laragh JH. Circ Res, Malignant hypertension resulting from deoxycorticosterone acetate and salt excess: role of renin and sodium in vascular changes., 1975, 36, 300-309,","journal-title":"Circ Res"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1161\/CIRCULATIONAHA.106.653964","volume":"115","author":"G\u00fcder G.","year":"2007","unstructured":"G\u00fcder G, Bauersachs J, Frantz S. Circulation, Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure., 2007, 115, 1754-1761,","journal-title":"Circulation"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurjhf\/hft100","volume":"15","author":"Girerd N.","year":"2013","unstructured":"Girerd N, Pang PS, Swedberg K. Eur J Heart Fail, Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: Analysis from the EVEREST trial., 2013, 15, 1228-1235,","journal-title":"Eur J Heart Fail"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jchf.2012.08.001","volume":"1","author":"Patel K.","year":"2013","unstructured":"Patel K, Fonarow GC, Kitzman DW. JACC Heart Fail, Aldosterone antagonists and outcomes in real-world older patients with heart failure and preserved ejection fraction., 2013, 1, 40-47,","journal-title":"JACC Heart Fail"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/ejhf.137","volume":"16","author":"Lund L.H.","year":"2014","unstructured":"Lund LH, Donal E, Oger E. Eur J Heart Fail, Association between cardiovascular vs. non-cardiovascular co-morbidities and outcomes in heart failure with preserved ejection fraction., 2014, 16, 992-1001,","journal-title":"Eur J Heart Fail"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.cardfail.2014.05.010","volume":"20","author":"Kurrelmeyer K.M.","year":"2014","unstructured":"Kurrelmeyer KM, Ashton Y, Xu J, Nagueh SF, Torre-Amione G, Deswal A. J Card Fail, Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction., 2014, 20, 560-568,","journal-title":"J Card Fail"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.cardfail.2011.04.007","volume":"17","author":"Deswal A.","year":"2011","unstructured":"Deswal A, Richardson P, Bozkurt B, Mann DL. J Card Fail, Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF)., 2011, 17, 634-642,","journal-title":"J Card Fail"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","volume":"309","author":"Edelmann F.","year":"2013","unstructured":"Edelmann F, Wachter R, Schmidt AG. JAMA, Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial., 2013, 309, 781-791,","journal-title":"JAMA"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"Pitt B.","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF. N Engl J Med, Spironolactone for heart failure with preserved ejection fraction., 2014, 370, 1383-1392,","journal-title":"N Engl J Med"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1056\/NEJMc1612601","volume":"376","author":"de Denus S.","year":"2017","unstructured":"de Denus S, O\u2019Meara E, Desai AS. N Engl J Med, Spironolactone Metabolites in TOPCAT - New Insights into Regional Variation., 2017, 376, 1690-1692,","journal-title":"N Engl J Med"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.2174\/1381612823666170206154706","volume":"23","author":"Faselis C.","year":"2017","unstructured":"Faselis C, Boutari C, Doumas M, Imprialos K, Stavropoulos K, Kokkinos P. Curr Pharm Des, Novel Drugs for Hypertension and Heart Failure: Struggling for a Place Under the Sun., 2017, 23, 1540-1550,","journal-title":"Curr Pharm Des"}],"container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/170097","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T21:42:54Z","timestamp":1558820574000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/170097\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,26]]},"references-count":25,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2019,4,26]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612825666190219140342","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4,26]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-01-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}